Addex Therapeutics Ltd (ADXN.SW)
CHF 0.06
(-8.5%)
CHF 0.06
(-8.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -10.22 Million CHF | 50.39% |
| 2022 | -20.43 Million CHF | -33.09% |
| 2021 | -14.94 Million CHF | -28.1% |
| 2020 | -12.41 Million CHF | 16.89% |
| 2019 | -14.31 Million CHF | -901.17% |
| 2018 | -1.5 Million CHF | 55.85% |
| 2017 | -3.26 Million CHF | -3.35% |
| 2016 | -3.12 Million CHF | -19.15% |
| 2015 | -4.17 Million CHF | -53.23% |
| 2014 | -1.66 Million CHF | 87.62% |
| 2013 | -13.75 Million CHF | 44.57% |
| 2012 | -24.5 Million CHF | 11.08% |
| 2011 | -28.04 Million CHF | 8.46% |
| 2010 | -30.55 Million CHF | -167.12% |
| 2009 | -39.85 Million CHF | 332.9% |
| 2008 | -20.04 Million CHF | 41.25% |
| 2007 | -33.25 Million CHF | -84.54% |
| 2006 | -17.99 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -785.15 Thousand CHF | 73.58% |
| 2024 Q2 | -1.31 Million CHF | -83.63% |
| 2023 FY | - CHF | 50.39% |
| 2023 Q4 | -2.6 Million CHF | -1.54% |
| 2023 Q3 | -2.56 Million CHF | -4.29% |
| 2023 Q2 | -2.45 Million CHF | -6.88% |
| 2023 Q1 | -2.29 Million CHF | 32.31% |
| 2022 Q1 | -5.67 Million CHF | -35.4% |
| 2022 Q3 | -4.08 Million CHF | 41.7% |
| 2022 FY | - CHF | -33.09% |
| 2022 Q2 | -7 Million CHF | -23.49% |
| 2022 Q4 | -3.39 Million CHF | 16.85% |
| 2021 Q1 | -2.53 Million CHF | -40.93% |
| 2021 FY | - CHF | -28.1% |
| 2021 Q2 | -4.41 Million CHF | -74.56% |
| 2021 Q3 | -3.48 Million CHF | 21.05% |
| 2021 Q4 | -4.19 Million CHF | -20.21% |
| 2020 FY | - CHF | 16.89% |
| 2020 Q4 | -1.79 Million CHF | 40.41% |
| 2020 Q3 | -3.01 Million CHF | -5.1% |
| 2020 Q2 | -2.86 Million CHF | 31.0% |
| 2020 Q1 | -4.15 Million CHF | -17.72% |
| 2019 Q3 | -3.47 Million CHF | 18.78% |
| 2019 Q1 | -3.04 Million CHF | -57.06% |
| 2019 FY | - CHF | -901.17% |
| 2019 Q4 | -3.52 Million CHF | -1.44% |
| 2019 Q2 | -4.28 Million CHF | -40.58% |
| 2018 FY | - CHF | 55.85% |
| 2018 Q3 | -1.94 Million CHF | -257.82% |
| 2018 Q2 | 1.22 Million CHF | -0.0% |
| 2018 Q1 | 1.22 Million CHF | 266.05% |
| 2018 Q4 | -1.94 Million CHF | 0.0% |
| 2017 Q3 | -740.33 Thousand CHF | 14.86% |
| 2017 FY | - CHF | -3.35% |
| 2017 Q4 | -740.33 Thousand CHF | 0.0% |
| 2017 Q2 | -869.57 Thousand CHF | 0.0% |
| 2017 Q1 | -869.57 Thousand CHF | -6.44% |
| 2016 Q1 | -734.95 Thousand CHF | -39.44% |
| 2016 FY | - CHF | -19.15% |
| 2016 Q4 | -816.96 Thousand CHF | 0.0% |
| 2016 Q3 | -816.96 Thousand CHF | -11.16% |
| 2016 Q2 | -734.95 Thousand CHF | 0.0% |
| 2015 Q4 | -527.07 Thousand CHF | -0.96% |
| 2015 Q2 | -771.89 Thousand CHF | 0.0% |
| 2015 Q1 | -771.89 Thousand CHF | 0.13% |
| 2015 FY | - CHF | -53.23% |
| 2015 Q3 | -522.04 Thousand CHF | 32.37% |
| 2014 Q1 | -452.95 Thousand CHF | -366.96% |
| 2014 Q4 | -772.88 Thousand CHF | 0.0% |
| 2014 Q3 | -772.88 Thousand CHF | -70.63% |
| 2014 Q2 | -452.95 Thousand CHF | 0.0% |
| 2014 FY | - CHF | 87.62% |
| 2013 Q3 | 104.99 Thousand CHF | 101.69% |
| 2013 Q4 | -97 Thousand CHF | -192.39% |
| 2013 FY | - CHF | 44.57% |
| 2013 Q1 | -6.19 Million CHF | -11.63% |
| 2013 Q2 | -6.19 Million CHF | 0.0% |
| 2012 Q3 | -5.54 Million CHF | 0.0% |
| 2012 FY | - CHF | 11.08% |
| 2012 Q4 | -5.54 Million CHF | 0.0% |
| 2011 FY | - CHF | 8.46% |
| 2010 FY | - CHF | -167.12% |
| 2009 FY | - CHF | 332.9% |
| 2008 FY | - CHF | 41.25% |
| 2007 FY | - CHF | -84.54% |
| 2006 FY | - CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BB Biotech AG | -201.25 Million CHF | 94.918% |
| Basilea Pharmaceutica AG | 29.49 Million CHF | 134.679% |
| Evolva Holding SA | -98.35 Million CHF | 89.601% |
| Idorsia Ltd | -254.55 Million CHF | 95.982% |
| Kuros Biosciences AG | -10.4 Million CHF | 1.733% |
| Molecular Partners AG | -59.51 Million CHF | 82.813% |
| Relief Therapeutics Holding AG | -108.2 Million CHF | 90.547% |
| Santhera Pharmaceuticals Holding AG | 79.17 Million CHF | 112.919% |